Reliant Investment Partners’s Boston Scientific BSX Stock Holding History

Reliant Investment Partners’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,350	Closed	-$229K	–	111
2025 Q3	$229K	Hold	2,350	–	–	0.18%	103
2025 Q2	$252K	Hold	2,350	–	–	0.22%	98
2025 Q1	$237K	Buy	+2,350	New	+$237K	0.24%	82

Other funds holding BSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Reliant Investment Partners's BSX Position: Q4 2025 in Review

Reliant Investment Partners sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 2,350 shares — an estimated $229K sold.

Reliant Investment Partners first reported a position in BSX in Q1 2025 and held it in 3 quarters. The position peaked at $252K in Q2 2025. 1,795 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

Reliant Investment Partners reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
Reliant Investment Partners sold 2,350 Boston Scientific shares in Q4 2025, an estimated $229K.
Reliant Investment Partners first reported a position in Boston Scientific in Q1 2025 and held it in 3 quarters.
Reliant Investment Partners's Boston Scientific position peaked at $252K in Q2 2025.
1,795 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on Reliant Investment Partners's 13F filing for Q4 2025, filed 6 Feb 2026.